Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Acetaminophen May Get Pulled From Rx Combo Products After Narrow Vote

Executive Summary

FDA will have to balance the goal of preventing liver injury with concerns about access to treatment and narcotic abuse as it weighs whether to implement a joint advisory committee's narrow recommendation to remove acetaminophen from combination Rx products

You may also be interested in...

FDA Takes Advisory Committee Off Life Support, Adds Analgesics To Title

The Anesthetics and Life Support Drugs Advisory Committee discussed analgesics at 11 of 14 meetings during the past four years, anesthetics at three, and life support drugs at none.

FDA Restrictions On Rx Acetaminophen Show How Practical Concerns Influence Safety Actions

Because the agency can move faster on Rx products than OTCs, non-prescription products will have higher acetaminophen levels than Rx drugs, at least for the time being.

CDER Ombudsman Referees Increasing Number Of Internal Scientific Disputes

Last year, Virginia Behr, the ombudsman for FDA's Center for Drug Evaluation and Research, dealt with the usual consumer and industry complaints about off-label drug promotion, marketing of unapproved drugs and unethical research conduct. But she also played a greater role mediating scientific disputes between FDA staff

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts